News

The double-blind, two-arm parallel group study will randomize 120 patients to receive 12 mg of Bekinda or placebo once daily for eight weeks. The primary endpoint is the

Venclexta is being developed by AbbVie and Genentech. It is the first therapy approved by the FDA, targeting the the B-cell lymphoma 2 (BCL-2) protein which supports cancer

Dr. Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented: "Whilst there have been some recent and significant advances in the treatment of squamous cell carcinoma of

In its report on that inspection, the Thai FDA stated that, "The facility is built according to the pre-approved floor plan and is now deemed suitable for the

IONIS-TTRRx is currently being evaluated by IONIS in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. A Phase 3 study, CARDIO-TTR, is

This collaboration is the first to expand on Immunovaccine’s previously announced research project in which the company will apply its DepoVax™ platform to development of a Zika virus

The approval was based on data from the SENSE clinical study, which evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with

ANAVEX 3-71 is a preclinical drug candidate with a novel mechanism of action through sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has demonstrated to enhance neuroprotection

The companies formed an alliance in 2014 to develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor. The new milestone means Eli Lilly will pay